Hard capsules filled with liquid crystalline phase matrix for sustained oral drug delivery
Ying Huang,Yujun Xiao,Chune Zhu,Heqing Huang,Chuanbin Wu
2013-01-01
Abstract:SUMMARY A novel sustained-release carrier for oral drug delivery was developed by introducing liquid crystalline cubic phase precursor into hard capsules. Hydrophilic Doxycycline Hydrochloride (DOXY) and lipophilic Meloxicam (MLX) as model drugs were loaded in precursor, which was in solid state at ambient temperature, liquated near body temperature, and transformed into cubic phase with water uptaking. Up to 24 h-sustained release was achieved in vitro successfully by using this system. INTRODUCTION In the past decade, liquid crystalline cubic phase as a delivery system has drawn great interest in cosmetic and chemical industries, as well as in the field of pharmaceutics. This is because (1) both hydrophilic and lipophilic drugs can be loaded in this system; (2) the system has good biocompatibility and adhesivity; (3) the system can isolate sensitive drugs such as proteins and peptides to improve their stability; and (4) the system has sustained release properties. It is difficult to process highly viscous liquid crystalline cubic phase matrix into an appropriate dosage form for oral delivery. Usually the precursor was filled into soft capsules. However, it is well known that the liquid-filled hard capsules could greatly simplify the manufacturing process, improve drug stability and bioavailability by using appropriate fillers, generate sustained release profiles, cover bitterness, and greatly improve the uniformity of high potency drug. Therefore, a novel technique using cubic liquid crystalline phase as drug carrier filled in hard capsules was developed. DOXY and MLX were employed to establish oral sustainedrelease delivery system for hydrophilic and lipophilic drugs respectively based on liquid crystalline cubic phase matrix. EXPERIMENTAL METHODS Glycerol monooleate (GMO) was chosen as the base material for liquid cubic phase. Differential scanning calorimetry (DSC) was used to study the melting properties of the formulation, while visual observation, Polarizing microscope and Small Angel X-ray Scattering (SAXS) were used to investigate the liquid crystalline phase of GMO-water binary system, GMO-drug-water ternary system, and GMO-drug-excipient-water quaternary system. The conditions for phase transition from cubic phase precursor to cubic phase matrix were determined. Influences of drug solubility, drug loading, type and content of additives (PEG 400, PEG 1000, PEG 6000, Tween 80 and Gelucire 39/01) on release profiles of precursor capsules were investigated. With drug loading, content of PEG 1000 and Tween 80 as three factors, influence factor test and L9(3) orthogonal design test were used to optimize the precursor formulations containing DOXY and MLX respectively. In vitro release behaviors of the optimal precursor capsules were compared with those of drug powder capsules and marketed conventional tablets. Changes in appearance and transition of liquid crystalline phase were also investigated during drug release. RESULTS AND DISCUSSION Conditions for change from liquid crystalline precursor to cubic phase were determined. The precursor capsules could melt at about 37°C and form cubic phase after 30% (wt) water-uptake. The optimized precursor formulation either contained 5% DOXY, 80% GMO and 15% Gelucire 39/01, or contained 2.5% MLX, 80% GMO 80%, 15%PEG1000 and 2.5% Tween 80. In vitro release profiles showed obvious 24 hsustained release with no burst effect from the precursor capsules in comparison with drug power capsules and marketed conventional tablets (Figure 1). Figure 1. Release profiles of optimized precursor capsules, drug powder capsules, and marketed tablets, (A) DOXY in water and (B) MLX in pH 7.2 PBS at 37°C (n=3). The Higuchi fitting equation was y=15.27t+5.3263 (r of 0.9991) for DOXY release from precursor capsules, and y=17.59t-2.5284 (r of 0.9990) for MLX release, indicating diffusion-control was the main release mechanism for precursor capsules as erosion playing a key role during drug release process. Figure 2. Polarizing microscope photos and SAXS diffractograms of optimized precursor capsules containing MLX (A) and DOXY (B) after 1 h (I) and 24 h (II) release studies. Examination of changes in appearance and phase transformation of precursor capsules during the release process showed that DOXY changed to lamellar phase while MLX formed cubic phase after 1 h (Figure 2). The capsules went through a phase transition to form cubic phase and finally to hexagonal phase after 24 h. CONCLUSION A novel preparation of cubic liquid crystalline phase matrix was innovatively developed in combination of liquid-filled hard capsules for oral delivery. This preparation can incorporate drugs with various properties, provide up to 24 h sustained release, easily deal with the high viscous precursor, and be thermodynamically stable with excess of water. In addition, the precursor capsules can melt under body temperature and form cubic phase. This sustained-release formulation provided a new and meaningful approach to oral delivery of cubic liquid crystalline phase, and is applicable for industrial production. REFERENCES 1. Lee, K.W.; Nguyen, T.H. Int. J. Pharm. 2009, 365, (1-2), 190-199. 2. Madhurilatha, T.; Paruchuri, S. K. IJRPC. 2011, 1, (3), 535-541. ACKNOWLEDGMENTS Financial support was provided by the National Natural Science Foundation of China (No. 81173002). And thanks to Danisk Co. Ltd (Denmark) for their generous donation. AI AII